EQNSX
Price
$23.16
Change
+$0.08 (+0.35%)
Updated
Jul 25 closing price
Net Assets
668.42M
RMFCX
Price
$60.41
Change
+$0.27 (+0.45%)
Updated
Jul 25 closing price
Net Assets
110.54B
Interact to see
Advertisement

EQNSX vs RMFCX

Header iconEQNSX vs RMFCX Comparison
Open Charts EQNSX vs RMFCXBanner chart's image
MFS Equity Income R2
Price$23.16
Change+$0.08 (+0.35%)
VolumeN/A
Net Assets668.42M
American Funds American Mutual R3
Price$60.41
Change+$0.27 (+0.45%)
VolumeN/A
Net Assets110.54B
EQNSX vs RMFCX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
EQNSX vs. RMFCX commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EQNSX is a Buy and RMFCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 111B vs. EQNSX (668M). EQNSX pays higher dividends than RMFCX: EQNSX (1.72) vs RMFCX (1.27). EQNSX was incepted earlier than RMFCX: EQNSX (13 years) vs RMFCX (23 years). EQNSX (1.20) is less costly to investors than RMFCX (0.91). EQNSX is a more actively managed with annual turnover of: 45.00 vs. RMFCX (31.00). EQNSX has a lower initial minimum investment than RMFCX: EQNSX (0) vs RMFCX (250). RMFCX annual gain was more profitable for investors over the last year : 11.38 vs. EQNSX (8.27). EQNSX return over 5 years is better than : 64.60 vs. RMFCX (60.49).
EQNSXRMFCXEQNSX / RMFCX
Total Expense Ratio1.140.91125%
Annual Report Gross Expense Ratio1.200.91132%
Fund Existence13 years23 years-
Gain YTD11.01811.34797%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets668M111B1%
Annual Yield % from dividends1.721.27135%
Returns for 1 year8.2711.3873%
Returns for 3 years36.3430.87118%
Returns for 5 years64.6060.49107%
Returns for 10 years100.4981.82123%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATHE6.550.87
+15.32%
Alterity Therapeutics Limited
HDSN8.530.25
+3.08%
Hudson Technologies
DEI15.550.05
+0.32%
Douglas Emmett
DVA145.170.40
+0.28%
DaVita
DRMA0.70N/A
-0.01%
Dermata Therapeutics Inc.